Browsing Tag
AHA 2025
4 posts
Can AI predict heart failure years earlier? Inside Anumana’s breakthrough AHA 2025 results
Anumana’s FDA-cleared ECG-AI platform enhances heart failure prediction and expands into perioperative care with Boston Scientific’s backing. Learn more.
AHA 2025: New REDUCE-IT results reveal Vascepa lowers heart attack and stroke risk even when LDL-C is optimal
Find out how AHA 2025 REDUCE-IT results show Vascepa reduces heart attack and stroke risk even when LDL-C is optimal — reshaping cardiovascular prevention.
Why Innovent Biologics and SanegeneBio believe IBI3016 could change hypertension treatment
Innovent Biologics and SanegeneBio reveal strong Phase 1 data for IBI3016 at AHA 2025. Discover how this RNAi therapy could redefine hypertension treatment.
AHA 2025 spotlight: sotagliflozin data spark debate on benefits in HFpEF patients without diabetes
Find out how sotagliflozin’s debated HFpEF results at AHA 2025 could change heart-failure therapy beyond diabetes.